Birol Vural
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Birol Vural has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Sebiha Özkan
Department of Obstetrics and Gynecology, School of Medicine, Kocaeli University, Kocaeli, Turkey
7 shared publications - Fisun Vural
Department of Gynecology and Obstetrics, University of Health Sciences Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
6 shared publications - Seyhun Solakoglu
Department of Histology and Embryology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
5 shared publications Eray Caliskan
Department of Obstetric and Gynecology, School of Medicine, Kocaeli University, Kocaeli, Turkey
4 shared publicationsHarika Bodur
4 shared publicationsAydın Çorakçı
Department of Obstetrics and Gynecology, At Kocaeli University School of Medicine, Tüpraş Sitesi, Güney Mahallesi, Körfez, Kocaeli, Turkey
3 shared publications
Latest Publications
- 24 December 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (4) , 1083-1090
The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology
Purpose The diagnosis of polycystic ovary syndrome (PCOS) remains a challenge to clinicians due to heterogeneous clinical presentation and diagnostic criteria. This study investigated the utilization of Anti-Müllerian hormone (AMH) alone or replacing polycystic ovarian morphology (PCOM) in the PCOS diagnostic criteria. Methods A total of 401 women were categorised as PCOS (n:154), nonPCOS with polycystic ovarian morphology (PCOM) (n:105), and nonPCOS with normal ovarian morphology (NOM) (n:142). First, the diagnostic performance of AMH for PCOS diagnosis in Rotterdam, Androgen Excess Society, and National Institutes of Health (NIH) criteria was analyzed. Second, AMH was used instead of PCOM in Rotterdam criteria and we searched diagnostic performance for PCOS phenotypes. Results AMH levels were positively correlated with LH, testosterone, hirsutism score, menstrual cycle length, and antral follicle count (p < 0.05). AMH alone had specificity and sensitivity for PCOS diagnosis were 84.9% and 72.4% in Rotterdam (AUC: 0.866); 84.4% and 72% in Androgen Excess Society (AUC: 0.857); 83.3% and 66.4% in National Institute of Health criteria (AUC: 0.825). AMH alone had satisfactory diagnostic potential for phenotype A, but not other phenotypes. The replacement of PCOM with AMH in Rotterdam criteria had a high diagnostic potential for PCOS (AUC: 0.934, sensitivity:97.4%, specificity: 90.67%). Phenotype A and phenotype D were diagnosed with 100% sensitivity and 94.5% specificity. Phenotype C was recognised with 96.15% sensitivity and 94.5% specificity. Conclusion AMH may be used with high diagnostic accuracy instead of PCOM in the Rotterdam PCOS criteria.
- 24 December 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (4) , 1083-1090
The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology
Purpose The diagnosis of polycystic ovary syndrome (PCOS) remains a challenge to clinicians due to heterogeneous clinical presentation and diagnostic criteria. This study investigated the utilization of Anti-Müllerian hormone (AMH) alone or replacing polycystic ovarian morphology (PCOM) in the PCOS diagnostic criteria. Methods A total of 401 women were categorised as PCOS (n:154), nonPCOS with polycystic ovarian morphology (PCOM) (n:105), and nonPCOS with normal ovarian morphology (NOM) (n:142). First, the diagnostic performance of AMH for PCOS diagnosis in Rotterdam, Androgen Excess Society, and National Institutes of Health (NIH) criteria was analyzed. Second, AMH was used instead of PCOM in Rotterdam criteria and we searched diagnostic performance for PCOS phenotypes. Results AMH levels were positively correlated with LH, testosterone, hirsutism score, menstrual cycle length, and antral follicle count (p < 0.05). AMH alone had specificity and sensitivity for PCOS diagnosis were 84.9% and 72.4% in Rotterdam (AUC: 0.866); 84.4% and 72% in Androgen Excess Society (AUC: 0.857); 83.3% and 66.4% in National Institute of Health criteria (AUC: 0.825). AMH alone had satisfactory diagnostic potential for phenotype A, but not other phenotypes. The replacement of PCOM with AMH in Rotterdam criteria had a high diagnostic potential for PCOS (AUC: 0.934, sensitivity:97.4%, specificity: 90.67%). Phenotype A and phenotype D were diagnosed with 100% sensitivity and 94.5% specificity. Phenotype C was recognised with 96.15% sensitivity and 94.5% specificity. Conclusion AMH may be used with high diagnostic accuracy instead of PCOM in the Rotterdam PCOS criteria.
- Open Access
- 1 January 2017
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 4 (3) , 218-224
The Impact of Body Mass Index and Insulin Resistance on IVF Outcomes of Polycystic Ovary Syndrome
To examine effects of body mass index (BMI) and insulin resistance (IR) on the in vitro fertilization (IVF) outcomes in women with polycystic ovary syndrome (PCOS). A total of 106 women with PCOS who underwent intracytoplasmic sperm injection were investigated. The patients were stratified into groups according to their BMI [healthy weight: BMI 2.5). The main outcome measures were reproductive and IVF outcomes with respect to BMI and IR. The basal hormonal evaluations, such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), LH/FSH, estradiol, testosterone, DHEAS, AMH, and antral follicle counts, were similar between the groups of BMI and IR. The number of retrieved oocytes, MII oocytes, embryo counts, and fertilization and pregnancy rates were similar between lean and overweight/obese PCOS with and without IR. Even though pregnancy and delivery rates per started cycle and embryo transfer were higher in healthy-weight women with PCOS than in overweight/obese patients, it did not reach statistical significance. Reproductive outcomes in women with PCOS according to BMI and IR were similar. Neither BMI nor IR had an independent effect on ovarian response and IVF success in young women with PCOS.
- 1 January 2017
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 4 (3) , 218-224
Open AccessThe Impact of Body Mass Index and Insulin Resistance on IVF Outcomes of Polycystic Ovary Syndrome
To examine effects of body mass index (BMI) and insulin resistance (IR) on the in vitro fertilization (IVF) outcomes in women with polycystic ovary syndrome (PCOS). A total of 106 women with PCOS who underwent intracytoplasmic sperm injection were investigated. The patients were stratified into groups according to their BMI [healthy weight: BMI 2.5). The main outcome measures were reproductive and IVF outcomes with respect to BMI and IR. The basal hormonal evaluations, such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), LH/FSH, estradiol, testosterone, DHEAS, AMH, and antral follicle counts, were similar between the groups of BMI and IR. The number of retrieved oocytes, MII oocytes, embryo counts, and fertilization and pregnancy rates were similar between lean and overweight/obese PCOS with and without IR. Even though pregnancy and delivery rates per started cycle and embryo transfer were higher in healthy-weight women with PCOS than in overweight/obese patients, it did not reach statistical significance. Reproductive outcomes in women with PCOS according to BMI and IR were similar. Neither BMI nor IR had an independent effect on ovarian response and IVF success in young women with PCOS.
- Open Access
- 30 September 2015
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 1 (1) , 26-29
Etanercept Tedavisinin Deneysel Endometriozisli Sıçan Modelinde Serum Malonaldialdehid Düzeylerine Etkisi
Amaç: Amacımız oluşturulan deneysel endometriozisli sıçan modelinde etanerceptin endometriozisi tedavi edebilme yeteneğini serum lipid peroksidasyonuna olan etkisi üzerinden değerlendirmekti.Yöntem: Bu deneysel çalışmada 30 adet Wistar albino cinsi dişi sıçan kullanıldı. Sıçanlardan 20’sinde endometriozis modeli cerrahi olarak oluşturulurken, 10’unda ise anestezi ve cerrahinin etkisini dışlamak amacıyla yalancı operasyon uygulandı. İlk operasyondan 4 hafta sonra sıçanların ektopik endometrial doku volümleri ikinci bir operasyonla değerlendirildi ve kan alındı. Daha sonra sıçanlar 3 gruba ayrıldı: Grup I (herhangi bir tedavi almamış, yalancı operasyon, n=10), grup II (2 ml/gün subkutan serum fizyolojik, endometriozis modeli, n=10), grup III (2 mg/kg/haftada 3 kez, subkutan etanercept, endometriozis modeli, n=10). İki haftalık tedavi sonrası sıçanların 3. operasyonla ektopik endometrial doku volümleri değerlendirildi ve 2. kanları alındı. Serum malondialdehid (MDA) düzeyleri spektrofotometrik olarak analiz edildi.Bulgular: Tedavi sonrası dönemde ektopik endometrial doku volümleri karşılaştırıldığında grup III te grup II ye göre anlamlı düşük sonuçlar elde edildi (p=0.000). Aynı zamanda grup III tedavi sonrası dönemde, tedavi öncesi döneme göre anlamlı düşük doku volüm değerleri gösterdi (p=0.005). Tedavi sonrası dönemde ise MDA düzeylerinde gruplar arası anlamlı farklılık mevcuttu (p=0.001). Tedavi sonrası dönemde MDA düzeyleri Grup III te grup II ye göre anlamlı düşüktü (p=0.001). Ek olarak, grup III te MDA düzeyleri tedavi sonrası dönemde öncesine göre anlamlı düşüktü (p=0.028).Sonuç: Çalışmamızın sonuçları bize etanerceptin serum lipid peroksidasyonu düşürücü etkisini ve endometriozis tedavisinde etkili bir şekilde kullanılabileceğini düşündürmektedir.
- 30 September 2015
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 1 (1) , 26-29
Open AccessEtanercept Tedavisinin Deneysel Endometriozisli Sıçan Modelinde Serum Malonaldialdehid Düzeylerine Etkisi
Amaç: Amacımız oluşturulan deneysel endometriozisli sıçan modelinde etanerceptin endometriozisi tedavi edebilme yeteneğini serum lipid peroksidasyonuna olan etkisi üzerinden değerlendirmekti.Yöntem: Bu deneysel çalışmada 30 adet Wistar albino cinsi dişi sıçan kullanıldı. Sıçanlardan 20’sinde endometriozis modeli cerrahi olarak oluşturulurken, 10’unda ise anestezi ve cerrahinin etkisini dışlamak amacıyla yalancı operasyon uygulandı. İlk operasyondan 4 hafta sonra sıçanların ektopik endometrial doku volümleri ikinci bir operasyonla değerlendirildi ve kan alındı. Daha sonra sıçanlar 3 gruba ayrıldı: Grup I (herhangi bir tedavi almamış, yalancı operasyon, n=10), grup II (2 ml/gün subkutan serum fizyolojik, endometriozis modeli, n=10), grup III (2 mg/kg/haftada 3 kez, subkutan etanercept, endometriozis modeli, n=10). İki haftalık tedavi sonrası sıçanların 3. operasyonla ektopik endometrial doku volümleri değerlendirildi ve 2. kanları alındı. Serum malondialdehid (MDA) düzeyleri spektrofotometrik olarak analiz edildi.Bulgular: Tedavi sonrası dönemde ektopik endometrial doku volümleri karşılaştırıldığında grup III te grup II ye göre anlamlı düşük sonuçlar elde edildi (p=0.000). Aynı zamanda grup III tedavi sonrası dönemde, tedavi öncesi döneme göre anlamlı düşük doku volüm değerleri gösterdi (p=0.005). Tedavi sonrası dönemde ise MDA düzeylerinde gruplar arası anlamlı farklılık mevcuttu (p=0.001). Tedavi sonrası dönemde MDA düzeyleri Grup III te grup II ye göre anlamlı düşüktü (p=0.001). Ek olarak, grup III te MDA düzeyleri tedavi sonrası dönemde öncesine göre anlamlı düşüktü (p=0.028).Sonuç: Çalışmamızın sonuçları bize etanerceptin serum lipid peroksidasyonu düşürücü etkisini ve endometriozis tedavisinde etkili bir şekilde kullanılabileceğini düşündürmektedir.
- 3 February 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 288 (1) , 213-220
The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin
Polycystic ovary syndrome (PCOS) is considered as the most common endocrinopathy among women of reproductive age. Oral contraceptives (OCs) and metformin are one of the main drug groups in the long-term treatment of PCOS. This study was undertaken to investigate the effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ultrasonographic markers, body fat mass (BFM) index, leptin-ghrelin. This was a prospective clinical study conducted at Kocaeli University Department of Obstetrics and Gynecology on 42 PCOS patients. Patients were randomly allocated into two groups [Group I (n = 22): drospirenone-ethinyl estradiol (DEE); Group II (n = 20): drospirenone-ethinyl estradiol + metformin (M)] according to Body Mass Index (BMI) findings. Patients were evaluated in terms of leptin-ghrelin, ultrasound, and body fat distribution before and 6 months after therapy. Main outcome measures were to investigate the effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, BFM index, leptin, and ghrelin. In patients with higher BMI, ovarian volume, numbers of follicles, stromal area, and echogenicity have been reported to be larger. In group II, a negative correlation between ghrelin and abdominal fat mass after treatment has been noted, whereas in group I a positive correlation between leptin and abdominal fat mass after treatment has been observed. Addition of metformin could have beneficial effects on abdominal fat mass. Stromal area measurement and assessment of fat mass with Dual X-ray Absorptiometry could be helpful as a quantitative way of measurement.
- 3 February 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 288 (1) , 213-220
The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin
Polycystic ovary syndrome (PCOS) is considered as the most common endocrinopathy among women of reproductive age. Oral contraceptives (OCs) and metformin are one of the main drug groups in the long-term treatment of PCOS. This study was undertaken to investigate the effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ultrasonographic markers, body fat mass (BFM) index, leptin-ghrelin. This was a prospective clinical study conducted at Kocaeli University Department of Obstetrics and Gynecology on 42 PCOS patients. Patients were randomly allocated into two groups [Group I (n = 22): drospirenone-ethinyl estradiol (DEE); Group II (n = 20): drospirenone-ethinyl estradiol + metformin (M)] according to Body Mass Index (BMI) findings. Patients were evaluated in terms of leptin-ghrelin, ultrasound, and body fat distribution before and 6 months after therapy. Main outcome measures were to investigate the effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, BFM index, leptin, and ghrelin. In patients with higher BMI, ovarian volume, numbers of follicles, stromal area, and echogenicity have been reported to be larger. In group II, a negative correlation between ghrelin and abdominal fat mass after treatment has been noted, whereas in group I a positive correlation between leptin and abdominal fat mass after treatment has been observed. Addition of metformin could have beneficial effects on abdominal fat mass. Stromal area measurement and assessment of fat mass with Dual X-ray Absorptiometry could be helpful as a quantitative way of measurement.
- 29 December 2010
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 27 (10) , 767-774
Is sildenafil citrate affect endometrial receptivity? an immunohistochemical study
The authors aimed to investigate the effect of sildenafil citrate (Sc) on expressions of β3 integrin and vascular endothelial growth factor (VEGF), which is taking part in endometrium receptivity in implantation window period in controlled ovarian hyperstimulation (COH) performed rats. In this study, Wistar albino female rats were used and were divided into four groups as control, COH, Sc, and COH + Sc groups. They were sacrificed on the third, fourth, and fifth day of pregnancy, uteruses were resected, and uteri sections were stained with immunohistochemical method and evaluated. β3 integrin immunoreactivity was most intensely observed in the endometrial glandular epithelium (GE) and stromal cells in the Sc group on the third day, whereas immunoreactivity was most intensely detected in the luminal epithelium (LE), GE, and stromal cells in the Sc group on the fourth day. VEGF immunoreactivity was most intensely observed in the endometrial LE in the Sc group on the third day, in the Sc and COH + Sc groups on the fourth day, and in the COH + Sc group on the fifth day. Our results indicated that Sc plays a role in both implantation and decidualization by affecting β3 integrin and VEGF expressions in implantation window period in rats.
- 29 December 2010
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 27 (10) , 767-774
Is sildenafil citrate affect endometrial receptivity? an immunohistochemical study
The authors aimed to investigate the effect of sildenafil citrate (Sc) on expressions of β3 integrin and vascular endothelial growth factor (VEGF), which is taking part in endometrium receptivity in implantation window period in controlled ovarian hyperstimulation (COH) performed rats. In this study, Wistar albino female rats were used and were divided into four groups as control, COH, Sc, and COH + Sc groups. They were sacrificed on the third, fourth, and fifth day of pregnancy, uteruses were resected, and uteri sections were stained with immunohistochemical method and evaluated. β3 integrin immunoreactivity was most intensely observed in the endometrial glandular epithelium (GE) and stromal cells in the Sc group on the third day, whereas immunoreactivity was most intensely detected in the luminal epithelium (LE), GE, and stromal cells in the Sc group on the fourth day. VEGF immunoreactivity was most intensely observed in the endometrial LE in the Sc group on the third day, in the Sc and COH + Sc groups on the fourth day, and in the COH + Sc group on the fifth day. Our results indicated that Sc plays a role in both implantation and decidualization by affecting β3 integrin and VEGF expressions in implantation window period in rats.
- Open Access
- 1 September 2010
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 11 (3) , 131-136
Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines
The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines. Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research. Endometrium cancer cell lines obtained from three patients were used for this study. After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium. Cells were incubated for 24 hours at 37ºC in 5% CO2. GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells. Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72(th) hours of incubation. The percentage of apoptotic cells was evaluated by TdT mediated biotin-dUTP nick-end labeling (TUNEL) method; cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation. Apoptotic index in grade I EEC cell line among ganirelixoctreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p<0.001, p=0.001). The number of apoptotic cells in grade II EEC cell line among leuprolide-octreotide and leuprolide were significantly (p<0.001, p<0.001) higher than in controls. In grade III EEC cell line, the number of TUNEL positive cells among leuprolide, ganirelix and ganirelixoctreotide therapiy groups were significantly higher than in untreated control. Time dependent antiproliferative effect was obtained with leuprolide and leuprolide-octreotide in grade I EEC (p<0.001, p<0.001). Grade II EEC cell line is not influenced by hormonotherapies. However, the antiproliferative effect was obtained with ganirelix, leuprolide and leuprolide-octreotide in grade III cell line. GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.
- 1 September 2010
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 11 (3) , 131-136
Open AccessEffect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines
The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines. Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research. Endometrium cancer cell lines obtained from three patients were used for this study. After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium. Cells were incubated for 24 hours at 37ºC in 5% CO2. GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells. Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72(th) hours of incubation. The percentage of apoptotic cells was evaluated by TdT mediated biotin-dUTP nick-end labeling (TUNEL) method; cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation. Apoptotic index in grade I EEC cell line among ganirelixoctreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p<0.001, p=0.001). The number of apoptotic cells in grade II EEC cell line among leuprolide-octreotide and leuprolide were significantly (p<0.001, p<0.001) higher than in controls. In grade III EEC cell line, the number of TUNEL positive cells among leuprolide, ganirelix and ganirelixoctreotide therapiy groups were significantly higher than in untreated control. Time dependent antiproliferative effect was obtained with leuprolide and leuprolide-octreotide in grade I EEC (p<0.001, p<0.001). Grade II EEC cell line is not influenced by hormonotherapies. However, the antiproliferative effect was obtained with ganirelix, leuprolide and leuprolide-octreotide in grade III cell line. GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.
- 26 November 2008
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 280 (1) , 19-24
Comparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial
To compare efficacy and safety of vaginal misoprostol (PGE1 analog) with dinoprostone (PGE2 analog) vaginal insert for labor induction in term pregnancies. A total of 112 women with singleton pregnancies of ≥37 weeks of gestation, and low Bishop scores underwent labor induction. The subjects were randomized to receive either 50 μg misoprostol intravaginally every 4 h to a maximum of five doses or a 10 mg dinoprostone vaginal insert for a maximum of 12 h. Time interval from induction to vaginal delivery, vaginal delivery rates within 12 and 24 h, requirement of oxytocin augmentation, incidence of tachysystole and uterine hyperstimulation, mode of delivery, rate of cesarean section due to fetal distress and neonatal outcome were outcome measures. Student’s t test, Chi square test, Fischer’s exact test were used for statistical analysis. Time interval from induction to vaginal delivery was found to be significantly shorter in misoprostol group when compared to dinoprostone subjects (680 ± 329 min vs. 1070 ± 435 min, P < 0.001). Vaginal delivery rates within 12 h were found to be significantly higher with misoprostol induction [n = 37 (66%) vs. n = 25 (44.6%); P = 0.02], whereas vaginal delivery rates in 24 h did not differ significantly between groups [n = 41 (73.2%) vs. n = 36 (64.2%); P = 0.3]. More subjects required oxytocin augmentation in dinoprostone group [n = 35 (62.5%) vs. n = 20 (35.7%), P = 0.005] and cardiotocography tracings revealed early decelerations occurring more frequently with misoprostol induction (10.7 vs. 0%, P = 0.03). Tachysystole and uterine hyperstimulation, mode of delivery, rate of cesarean sections due to fetal distress and adverse neonatal outcome were not demonstrated to be significantly different between groups (P = 1, P = 0.5, P = 0.4, P = 0.22, P = 0.5). Using vaginal misoprostol is an effective way of labor induction in term pregnant women with unfavorable cervices, since it is associated with a shorter duration of labor induction and higher rates of vaginal delivery within 12 h. Misoprostol and dinoprostone are equally safe, since misoprostol did not result in a rise in maternal and neonatal morbidity, namely, tachysystole, uterine hyperstimulation, cesarean section rates and admission to neonatal intensive care units as reported previously in literature.
- 26 November 2008
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 280 (1) , 19-24
Comparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial
To compare efficacy and safety of vaginal misoprostol (PGE1 analog) with dinoprostone (PGE2 analog) vaginal insert for labor induction in term pregnancies. A total of 112 women with singleton pregnancies of ≥37 weeks of gestation, and low Bishop scores underwent labor induction. The subjects were randomized to receive either 50 μg misoprostol intravaginally every 4 h to a maximum of five doses or a 10 mg dinoprostone vaginal insert for a maximum of 12 h. Time interval from induction to vaginal delivery, vaginal delivery rates within 12 and 24 h, requirement of oxytocin augmentation, incidence of tachysystole and uterine hyperstimulation, mode of delivery, rate of cesarean section due to fetal distress and neonatal outcome were outcome measures. Student’s t test, Chi square test, Fischer’s exact test were used for statistical analysis. Time interval from induction to vaginal delivery was found to be significantly shorter in misoprostol group when compared to dinoprostone subjects (680 ± 329 min vs. 1070 ± 435 min, P < 0.001). Vaginal delivery rates within 12 h were found to be significantly higher with misoprostol induction [n = 37 (66%) vs. n = 25 (44.6%); P = 0.02], whereas vaginal delivery rates in 24 h did not differ significantly between groups [n = 41 (73.2%) vs. n = 36 (64.2%); P = 0.3]. More subjects required oxytocin augmentation in dinoprostone group [n = 35 (62.5%) vs. n = 20 (35.7%), P = 0.005] and cardiotocography tracings revealed early decelerations occurring more frequently with misoprostol induction (10.7 vs. 0%, P = 0.03). Tachysystole and uterine hyperstimulation, mode of delivery, rate of cesarean sections due to fetal distress and adverse neonatal outcome were not demonstrated to be significantly different between groups (P = 1, P = 0.5, P = 0.4, P = 0.22, P = 0.5). Using vaginal misoprostol is an effective way of labor induction in term pregnant women with unfavorable cervices, since it is associated with a shorter duration of labor induction and higher rates of vaginal delivery within 12 h. Misoprostol and dinoprostone are equally safe, since misoprostol did not result in a rise in maternal and neonatal morbidity, namely, tachysystole, uterine hyperstimulation, cesarean section rates and admission to neonatal intensive care units as reported previously in literature.
- 24 April 2008
- Published by Springer Nature in Journal of Perinatology
- Vol. 28 (7) , 468-474
Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic and neural cell adhesion molecule in pregnancies with small for gestational age fetuses
Objective: Study Design: Result: Conclusion:
- 24 April 2008
- Published by Springer Nature in Journal of Perinatology
- Vol. 28 (7) , 468-474
Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic and neural cell adhesion molecule in pregnancies with small for gestational age fetuses
Objective: Study Design: Result: Conclusion:
- 1 January 2008
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 21 (11) , 831-838
Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic, and neural cell adhesion molecule in preeclampsia
Objective. To investigate placental expression of insulin-like growth factor-I (IGF-I), fibroblast growth factor-basic (FGF-b), and neural cell adhesion molecule (N-CAM) in preeclampsia. Study design. An immunohistochemical analysis using IGF-I, FGF-b, and N-CAM antibodies was conducted on 4% paraformaldehyde-fixed placental tissues of preeclamptic patients (N = 14) and normotensive pregnant subjects (N = 10). Immunostaining patterns of chorionic villi and amniochorionic membranes were assessed. Results. Significantly increased FGF-b and N-CAM immunoreactivities in cytotrophoblasts and increased FGF-b immunoreactivity in capillary endothelium of chorionic villi of preeclamptic subjects were noted. Significantly increased FGF-b and decreased N-CAM immunoreactivities in extravillous trophoblasts and decidual cells of amniochorionic membranes obtained from preeclamptic subjects were demonstrated. Additionally, a significantly increased IGF-I immunoreactivity was shown in decidual cells of preeclamptic cases. Conclusion. Investigation of the regional distribution of IGF-I, FGF-b, and N-CAM at the maternal–fetal interface establishes a better understanding of cell-specific altered growth processes, which may be associated with the pathogenesis of preeclampsia.
- 1 January 2008
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 21 (11) , 831-838
Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic, and neural cell adhesion molecule in preeclampsia
Objective. To investigate placental expression of insulin-like growth factor-I (IGF-I), fibroblast growth factor-basic (FGF-b), and neural cell adhesion molecule (N-CAM) in preeclampsia. Study design. An immunohistochemical analysis using IGF-I, FGF-b, and N-CAM antibodies was conducted on 4% paraformaldehyde-fixed placental tissues of preeclamptic patients (N = 14) and normotensive pregnant subjects (N = 10). Immunostaining patterns of chorionic villi and amniochorionic membranes were assessed. Results. Significantly increased FGF-b and N-CAM immunoreactivities in cytotrophoblasts and increased FGF-b immunoreactivity in capillary endothelium of chorionic villi of preeclamptic subjects were noted. Significantly increased FGF-b and decreased N-CAM immunoreactivities in extravillous trophoblasts and decidual cells of amniochorionic membranes obtained from preeclamptic subjects were demonstrated. Additionally, a significantly increased IGF-I immunoreactivity was shown in decidual cells of preeclamptic cases. Conclusion. Investigation of the regional distribution of IGF-I, FGF-b, and N-CAM at the maternal–fetal interface establishes a better understanding of cell-specific altered growth processes, which may be associated with the pathogenesis of preeclampsia.
- 1 June 2007
- Vol. 52 (6) , 563-6
Spontaneous vaginal expulsion of an infected necrotic cervical fibroid through a cervical fistula after uterine artery embolization: a case report.
Uterine artery embolization (UAE) is promising, minimally invasive therapy being offered to women for treatment of fibroids. Although it seems to be safe and effective, major complications and adverse outcomes have been reported. A patient treated with UAE for a huge cervical fibroid presented with an infected, necrotic cervical mass lesion 4 weeks after the procedure. Spontaneous vaginal expulsion of the infected cervical fibroid from the left lateral cervical fistula tract occurred 3 weeks later while the patient was receiving antibiotic therapy. After 6 months of intervention, an approximately 99% regression rate in the fibroid volume was achieved. The patient gave birth to a healthy, female infant following a spontaneous, uneventful pregnancy and vaginal delivery. UAE appears to be associated with a significant reduction in fibroid volume. Expulsion of the infected, necrotic parts of the fibroid after UAE may be accepted as a natural process. Warning the patient about this potential risk, early recognition of infective complications and lose follow up seem to be crucial to avoiding potentially fatal septic shock.
- 1 June 2007
- Vol. 52 (6) , 563-6
Spontaneous vaginal expulsion of an infected necrotic cervical fibroid through a cervical fistula after uterine artery embolization: a case report.
Uterine artery embolization (UAE) is promising, minimally invasive therapy being offered to women for treatment of fibroids. Although it seems to be safe and effective, major complications and adverse outcomes have been reported. A patient treated with UAE for a huge cervical fibroid presented with an infected, necrotic cervical mass lesion 4 weeks after the procedure. Spontaneous vaginal expulsion of the infected cervical fibroid from the left lateral cervical fistula tract occurred 3 weeks later while the patient was receiving antibiotic therapy. After 6 months of intervention, an approximately 99% regression rate in the fibroid volume was achieved. The patient gave birth to a healthy, female infant following a spontaneous, uneventful pregnancy and vaginal delivery. UAE appears to be associated with a significant reduction in fibroid volume. Expulsion of the infected, necrotic parts of the fibroid after UAE may be accepted as a natural process. Warning the patient about this potential risk, early recognition of infective complications and lose follow up seem to be crucial to avoiding potentially fatal septic shock.